✦ LIBER ✦

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients

✍ Scribed by Cure, Sandrine; Bianic, Florence; Gavart, Sandra; Curtis, Steve; Lee, Seina; Dusheiko, Geoffrey

Book ID: 121306758
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 841 KB
Volume: 17
Category: Article
ISSN: 1369-6998
DOI: 10.3111/13696998.2013.844159

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of telaprevir in comb

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients

✍ Cure, Sandrine; Bianic, Florence; Gavart, Sandra; Curtis, Steve; Lee, Seina; Dus 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 491 KB

1102 THE COST-EFFECTIVENESS OF TELAPREVI

1102 THE COST-EFFECTIVENESS OF TELAPREVIR (TVR) IN COMBINATION WITH PEGYLATED INTERFERON-ALFA AND RIBAVIRIN (PR) FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS

✍ Curtis, S.; Cure, S.; Gavart, S.; Dearden, L.; Fleischmann, J.; Ouwens, M.; Lee, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Pegylated interferon-alpha 2b–ribavirin

Pegylated interferon-alpha 2b–ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

✍ M. Derbala; A. Amer; A. Bener; A. C. Lopez; M. Omar; M. El Ghannam 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PIN27 The Cost-Effectiveness of Telaprev

PIN27 The Cost-Effectiveness of Telaprevir (TVR) in Combination With Pegylated Interferon-Alfa and Ribavirin (PR) for the Treatment of Genotype 1(G1) Chronic Hepatitis C Patients

✍ Cure, S.; Curtis, S.; Bianic, F.; Gavart, S.; Dearden, L.; Fleischmann, J.; Ouwe 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

COST-EFFECTIVENESS OF TELAPREVIR COMBINA

COST-EFFECTIVENESS OF TELAPREVIR COMBINATION THERAPY COMPARED TO PEGINTERFERON WITH RIBAVIRIN ALONE FOR NAIVE AND TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN POLAND

✍ Kaczor, M.P.; Wójcik, R.; Pawlik, D.; Skrzekowska-Baran, I.; Tronczynski, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Merimepodib, pegylated interferon, and r

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders

✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a